Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

sunitinib

ARX-SUNITINIB

sunitinib (ARX-SUNITINIB) is a vascular endothelial growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd.

EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01EX01
Patents linked 10
Pipeline programs 16
News articles 0
Drug details — sunitinib
Class
Antineoplastic and immunomodulating agents (L01)
Route
—
Patents
10
Programs
16
Data quality
0.83
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

sunitinib (ARX-SUNITINIB) is a vascular endothelial growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd.

Key facts

INN sunitinib
Brand ARX-SUNITINIB
Mechanism Vascular endothelial growth factor receptor inhibitor
Target Macrophage colony-stimulating factor 1 receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EX01
Originator Pfizer Australia Pty Ltd

Mechanism of action

Vascular endothelial growth factor receptor inhibitor

Primary target: Macrophage colony-stimulating factor 1 receptor

Approval history

Authority Status Date
EMA approved —
TGA approved —

Pipeline programs

Browse pipeline Sponsor programs
  1. BO40729 Phase 3 · HOFFMANN-LA ROCHE · Advanced Malignancies
  2. CA209-9ER Phase 3 · Bristol-Myers Squibb Australia · Advanced or Metastatic Renal Cell Carcinoma
  3. CGT9486 plus sunitinib Phase 3 · Cogent Biosciences · Advanced Gastrointestinal Stromal Tumors
  4. D5086C00001 Phase 3 · AstraZeneca · MET-driven, unresectable and locally advanced or metastatic
  5. DCC-2618-03-002 Phase 3 · Anaxis Pharma · Patients with Advanced Gastrointestinal Stromal Tumors
  6. MK-3475-426 Phase 3 · MSD Merck Sharp · Metastatic renal cell carcinoma
  7. MK-3475-679 Phase 3 · Incyte · Locally advanced/metastatic renal cell carcinoma
  8. sunitinib malate Phase 3 · Pfizer · Carcinoma, Hepatocellular

Related & competitor drugs

Browse all drugs
  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Related patents

Browse patents Pfizer Australia Pty Ltd patent hub

  1. US 12351581

    Compounds for FGFR inhibition

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11718576

    Compositions and methods comprising resveratrol

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11419943

    Polymer-sunitinib conjugates

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11406618

    Polymer-des-ethyl sunitinib conjugates

    Expires Mon Aug 04 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11339112

    Compositions and methods comprising resveratrol

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10836702

    Compositions and methods comprising resveratrol

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10682418

    Polymer-sunitinib conjugates

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10301248

    Compositions and methods comprising resveratrol

    Expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10220020

    Polymer-des-ethyl sunitinib conjugates

    Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9827326

    Polymer-sunitinib conjugates

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is sunitinib?

sunitinib (ARX-SUNITINIB) is a vascular endothelial growth factor receptor inhibitor. Associated with Pfizer Australia Pty Ltd.

What is the brand name for sunitinib?

ARX-SUNITINIB is a marketed brand name for sunitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.